SHANGHAI, China and MENLO PARK, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Decheng Capital, a healthcare investment firm, has added Dr. Dan Zabrowski as a venture partner to its investment team. Located in Shanghai and Silicon Valley, Decheng Capital has an outstanding track record of building successful companies both in China and the United States.
“I am honored and humbled to have Dan as our investment partner,” said Dr. Min Cui, founder and managing director of Decheng Capital. “He brings extensive knowledge, a long success record, and deep insights into both the diagnostic and pharmaceutical industries to us as well as our portfolio companies.
“We also share the same passion to support entrepreneurs and business partners who develop and provide solutions for prevention, diagnosis, and treatment of serious human diseases,” Min added.
A leader with a long and distinguished career, Dr. Zabrowski worked over 20 years for Roche in several key worldwide leadership positions including global head of regulatory affairs, development operations, and business development. He also was president of Ventana Medical Systems, and the Roche Sequencing Unit, and served as a board member of Chugai Pharmaceuticals.
During his tenure in Roche’s business development and diagnostics units, Dr. Zabrowski and his teams delivered more than 300 acquisition and partnership deals for the company.
Prior to joining Roche, Dr. Zabrowski worked for Syntex, Fujisawa (now Astellas), and G.D. Searle in their research and development organizations, and was adjunct assistant professor at the University of Illinois – Chicago’s School of Pharmacy. He earned his PhD in organic chemistry from Indiana University and his BA degree in chemistry from St. Louis University.
He noted, “I am excited to be working with Min and his team to build value for our shareholders and entrepreneurs. Decheng Capital is world-class in their ability to identify excellent opportunities and create value through their investments. I feel very fortunate to be joining this excellent organization.”
About Decheng Capital
Decheng Capital is a leading investment firm with more than $440 million in capital under management. It provides capital and strategic support to early-stage life sciences companies with revolutionary technologies and growth-stage healthcare companies with strong market presence.
Located in Shanghai and Silicon Valley, Decheng is a group of dedicated professionals with complementary expertise who have outstanding histories of building successful companies in both China and the United States. Founded in 2012, the company continues to help capitalize rapid growth of China’s healthcare industry as well as breakthroughs in life science research worldwide.